NeuroSense Therapeutics (NRSN) Retained Earnings (2020 - 2025)
NeuroSense Therapeutics (NRSN) posted Retained Earnings of -$47.8 million for Q4 2025, down 15.51% sequentially from -$41.4 million in Q2 2025, and down 30.35% YoY from -$68.6 million in Q4 2024.
NeuroSense Therapeutics (NRSN) Retained Earnings (2020 - 2025) Analysis & Trends
NeuroSense Therapeutics has reported Retained Earnings for 6 years, with the latest figure at -$47.8 million in Q4 2025.
- Quarterly Retained Earnings fell 30.35% year-over-year to -$47.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$47.8 million (down 30.35% YoY) and the FY2025 annual result came in at -$47.8 million, down 30.35% from the prior year.
- Retained Earnings slipped to -$47.8 million in Q4 2025 per NRSN's latest filing, from -$41.4 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$8.4 million in Q4 2021 and troughed at -$29.9 billion in Q2 2023.
- A 5-year average of -$2.0 billion and a median of -$29.1 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings tumbled 204107.08% in 2023, then jumped 99.89% in 2024.
- Over 5 years, Retained Earnings stood at -$8.4 million in 2021, then sank by 89.6% to -$16.0 million in 2022, then tumbled by 63.11% to -$26.1 million in 2023, then slumped by 40.35% to -$36.7 million in 2024, then tumbled by 30.35% to -$47.8 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered -$47.8 million, -$41.4 million, and -$36.7 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | -47.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -47.79 Mn |
| Jun 30, 2025 | -41.37 Mn |
| Dec 31, 2024 | -36.66 Mn |
| Sep 30, 2024 | -34.53 Mn |
| Jun 30, 2024 | -32.38 Mn |
| Mar 31, 2024 | -31.53 Mn |
| Dec 31, 2023 | -26.12 Mn |
| Sep 30, 2023 | -29.12 Mn |
| Jun 30, 2023 | -29.90 Bn |
| Mar 31, 2023 | -24.68 Mn |
| Dec 31, 2022 | -16.01 Mn |
| Sep 30, 2022 | -17.64 Mn |
| Jun 30, 2022 | -14.64 Mn |
| Mar 31, 2022 | -11.16 Mn |
| Dec 31, 2021 | -8.45 Mn |
| Dec 31, 2020 | -4.41 Mn |